Veoza vs. HRT: How the new non-hormonal option narrows treatment gaps

Veoza is now recommended by NICE for use on the NHS in England when HRT is unsuitable, and HRT remains the established first-line therapy for menopausal hot flushes. This comparison asks: on the same criteria of mechanism, eligible patients and likely clinical impact, how does Veoza alter treatment choices for women with moderate to severe vasomotor symptoms?

Veoza on NHS England: NICE recommendation, mechanism and reach

Veoza, also called fezolinetant, is a non-hormonal, once-daily tablet that blocks nerve pathways in the brain that trigger hot flushes and night sweats; the 45mg formulation is taken once a day. The pill was approved in 2023 and has now been recommended by the National Institute for Health and Care Excellence for treating moderate to severe menopausal hot flushes and night sweats on the NHS in England. NICE found fezolinetant can meaningfully reduce symptoms and judged it cost-effective, a decision that Helen Knight described as offering value for the taxpayer. Around 500, 000 women in England could be eligible for the treatment, particularly those who cannot take hormone replacement therapy because of underlying health conditions.

HRT: NICE position, formulations and limits for certain women

HRT remains the first-line treatment for menopausal vasomotor symptoms, and is available in multiple formulations including tablets, patches and gels. NICE states HRT has clear benefits, and it is thought most women with moderate to severe symptoms will continue to take it. However, HRT is unsuitable for some women—examples cited include those with a history of breast or ovarian cancer, blood clots, or untreated high blood pressure—leaving an unmet need for non-hormonal options for those patients.

NICE and NHS England: comparing Veoza and HRT on mechanism, eligibility and scale

Applying the same evaluative criteria—how each works, who can use it, and the scale of potential beneficiaries—clarifies where Veoza complements rather than replaces HRT. Mechanistically, Veoza acts on brain nerve pathways as a non-hormonal agent, while HRT restores hormonal levels through oestrogen and progestogen formulations. In eligibility terms, Veoza is specifically positioned for women for whom HRT is unsuitable; HRT remains appropriate for most others. On scale, NICE’s recommendation and NHS England endorsement mean Veoza could reach roughly 500, 000 women in England who lack safe HRT options.

Dr Sue Mann described the addition of Veoza as very welcome for women who are unable to or do not wish to take HRT, noting it could help hundreds of thousands manage symptoms and regain control of health. NICE emphasised the evidence of meaningful symptom reduction for fezolinetant while reiterating HRT’s established benefits and broad suitability.

Analysis — the finding: Veoza reduces a specific treatment gap by providing a clinically validated, cost-effective non-hormonal option for women who cannot use HRT, but it does not displace HRT as the first-line therapy for most patients. The immediate test of that finding will be whether NHS commissioning and clinician prescribing deliver access to eligible women and whether devolved administrations mirror NICE’s recommendation: Wales and Northern Ireland often follow NICE guidance, while Scotland’s separate medicines body will make its own decision. If NHS England maintains provision for eligible women, the comparison suggests Veoza will extend meaningful relief to the roughly 500, 000 women identified as candidates for a non-hormonal alternative.